Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2008

View Archived Issues

Preliminary study shows efficacy of aflibercept in diabetic macular edema

Phase II study data detail responses to tarenflurbil in mild Alzheimer's disease patients

Wyeth Pharmaceuticals terminates collaboration agreements with Solvay for bifeprunox

Pfizer receives approval for sustained-release Norvasc in Japan for hypertension and angina

GSK launches Imigran subcutaneous self-injection in Japan for migraine and cluster headache

Crucell enters vaccine development agreement with Wyeth

Data Safety Monitoring Board recommends continuation of HF-0220 phase II trial

LifeCycle reports positive top-line results for phase II LCP-Tacro trial

Paladin files new drug submission for Seasonique in Canada

Alexza's AZ-104 phase IIa trial meets primary endpoint

ALK-Abello announces positive third year results from Grazax trial

Array BioPharma reports positive phase II top-line results for ARRY-797

Novel agents for glaucoma disclosed in recent Pfizer patents

NeuroSearch reports positive and confirmatory results from TIPO-2 trial

Recent Organon and Activesite patents report novel antithrombotic agents

Novel therapeutic agents for respiratory disorders described in recent Boehringer Ingelheim patent

Reliable Abeta burden detection with Bayer's novel PET tracer

New beta3 adrenoceptor agonists may be useful in overactive bladder

Phase IIa multiple dose AVT-01 study shows safety but does not confirm efficacy

Results reported for phase II Juvista trial in scar revision and breast augmentation

FDA approves new dosage strengths of Endo's Opana

Pfizer to acquire Serenex and the rights to SNX-5422

Pharmacopeia initiates phase II clinical study of PS-433540 for hypertension

Data Safety Monitoring Board recommends continuation of Debio-9902 SR trial

GSK terminates development of Dacart in the treatment of malaria

MP-376 granted U.S. orphan drug status for the treatment of cystic fibrosis

Vermillion and Stanford University enter agreement for novel biomarker panel for PAD

CHMP recommends 300 mg tablet of sanofi-aventis and Bristol-Myers Squibb's Plavix

FDA grants fast track designation to Bioniche for Urocidin